{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:22:12Z","timestamp":1792858932008,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":1285,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The expression of Bruton tyrosine kinase (BTK) in B cells and innate immune cells provides essential downstream signaling for BCR, Fc receptors, and other innate immune cell pathways. The topical covalent BTK inhibitor PRN473 has shown durable, reversible BTK occupancy with rapid on-rate and slow off-rate binding kinetics and long residence time, resulting in prolonged, localized efficacy with low systemic exposure in vivo. Mechanisms of PRN473 include inhibition of IgE (Fc\u03b5R)\u2013mediated activation of mast cells and basophils, IgG (Fc\u03b3R)\u2013mediated activation of monocytes, and neutrophil migration. In vivo, oral PRN473 was efficacious and well tolerated in the treatment of canine pemphigus foliaceus. In this study, we evaluated in vitro selectivity and functionality, in vivo skin Ab inflammatory responses, and systemic pharmacology with topically administered PRN473. Significant dose-dependent inhibition of IgG-mediated passive Arthus reaction in rats was observed with topical PRN473 and was maintained when given 16 h prior to challenge, reinforcing extended activity with once-daily administration. Similarly, topical PRN473 resulted in significant dose-dependent inhibition of the mouse passive cutaneous anaphylaxis IgE-mediated reaction. Multiday treatment with topical PRN473 in rodents resulted in low-to-no systemic accumulation, suggesting that efficacy was mainly due to localized exposure. Reduced skin Ab inflammatory activity was also confirmed with oral PRN473. These preclinical studies provide a strong biologic basis for targeting innate immune cell responses locally in the skin, with rapid onset of action following once-daily topical PRN473 administration and minimal systemic exposure. Dose-dependent inhibition in these preclinical models of immune-mediated skin diseases support future clinical studies.<\/jats:p>","DOI":"10.4049\/immunohorizons.2100063","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:45:14Z","timestamp":1627559114000},"page":"581-589","source":"Crossref","is-referenced-by-count":19,"title":["Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7174-0482","authenticated-orcid":false,"given":"Yan","family":"Xing","sequence":"first","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A","family":"Chu","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Wadhwa","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Michael","family":"Bradshaw","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Shu","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C","family":"Foulke","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Loewenstein","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Nunn","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kolbot","family":"By","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasit","family":"Phiasivongsa","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8222-8153","authenticated-orcid":false,"given":"Claire L","family":"Langrish","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company , South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"2025010607440420000_r1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton\u2019s tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2025010607440420000_r2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1615\/CritRevImmunol.2018025184","article-title":"The role of Bruton\u2019s tyrosine kinase in immune cell signaling and systemic autoimmunity","volume":"38","author":"Rip","year":"2018","journal-title":"Crit. Rev. Immunol."},{"key":"2025010607440420000_r3","doi-asserted-by":"crossref","first-page":"e00034-18","DOI":"10.1128\/CMR.00034-18","article-title":"Organization of the skin immune system and compartmentalized immune responses in infectious diseases","volume":"32","author":"Quaresma","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"2025010607440420000_r4","doi-asserted-by":"crossref","first-page":"a015339","DOI":"10.1101\/cshperspect.a015339","article-title":"Immunology and skin in health and disease","volume":"4","author":"Richmond","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2025010607440420000_r5","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3400","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells","volume":"13","author":"Chang","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"2025010607440420000_r6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"2025010607440420000_r7","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2025010607440420000_r8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/jpet.111.187740","article-title":"RN486, a selective Bruton\u2019s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents","volume":"341","author":"Xu","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2025010607440420000_r9","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J. Immunol."},{"key":"2025010607440420000_r10","doi-asserted-by":"crossref","first-page":"R243","DOI":"10.1186\/ar4086","article-title":"Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus","volume":"14","author":"Hutcheson","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"2025010607440420000_r11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. [Published erratum appears in 2019 Mol. Cancer. 18: 79.]","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"2025010607440420000_r12","article-title":"Calquence (acalabrutinib) prescribing information","year":"2019"},{"key":"2025010607440420000_r13","article-title":"Imbruvica (ibrutinib) prescribing information","year":"2020"},{"key":"2025010607440420000_r14","article-title":"Brukinsa (zanubrutinib) prescribing information","year":"2019"},{"key":"2025010607440420000_r15","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J. Med. Chem."},{"key":"2025010607440420000_r16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11095-019-2752-y","article-title":"Population pharmacokinetics, efficacy exposure-response analysis, and model-based meta-analysis of fenebrutinib in subjects with rheumatoid arthritis [corrected]","volume":"37","author":"Chan","year":"2020","journal-title":"Pharm. Res."},{"key":"2025010607440420000_r17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"2025010607440420000_r18","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.16495.1","article-title":"Emerging small-molecule treatments for multiple sclerosis: focus on B cells","volume":"8","author":"Gregson","year":"2019","journal-title":"F1000Res."},{"key":"2025010607440420000_r19","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J. Immunol."},{"key":"2025010607440420000_r20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/ITT.S240874","article-title":"Bruton\u2019s tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE?","volume":"9","author":"Lorenzo-Vizcaya","year":"2020","journal-title":"ImmunoTargets Ther."},{"key":"2025010607440420000_r21","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.20431","article-title":"Proof-of-concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study","author":"Murrell","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"2025010607440420000_r22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nchembio.1817","article-title":"Prolonged and tunable residence time using reversible covalent kinase inhibitors","volume":"11","author":"Bradshaw","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"2025010607440420000_r23","doi-asserted-by":"crossref","first-page":"139.6","DOI":"10.4049\/jimmunol.194.Supp.139.6","article-title":"Efficacy in collagen induced arthritis models with a selective, reversible covalent Bruton\u2019s tyrosine kinase (BTK) inhibitor PRN473 is driven by durable target occupancy rather than extended plasma exposure (THER5P.904)","volume":"194","author":"Bisconte","year":"2015","journal-title":"J. Immunol."},{"key":"2025010607440420000_r24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bph.14090","article-title":"PRN473, an inhibitor of Bruton\u2019s tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling","volume":"175","author":"Herter","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"2025010607440420000_r25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/vde.12841","article-title":"Efficacy of a Bruton\u2019s Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus","volume":"31","author":"Goodale","year":"2020","journal-title":"Vet. Dermatol."},{"key":"2025010607440420000_r26","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.3390\/ijms20081811","article-title":"The dynamics of the skin\u2019s immune system","volume":"20","author":"Nguyen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"2025010607440420000_r27","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine kinases in autoimmune and inflammatory skin diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front. Immunol."},{"key":"2025010607440420000_r28","article-title":"A phase I, randomized, double-blind, placebo-controlled, ascending single dose study with a repeat-dose arm to evaluate the safety, tolerability and pharmacokinetics of topically administered PRN473 in healthy adult participants","author":"Principia Biopharma Inc., Clinical Network Services","year":"2020"},{"key":"2025010607440420000_r29","article-title":"A phase I, open-label, placebo-controlled, challenge study to evaluate the pharmacologic activity of topically administered PRN473 on the skin reaction induced by challenge agents via a skin prick in participants with immunoglobulin E-mediated allergies","author":"ACTRN12620000693921 ANZCTR (Australian New Zealand Clinical Trials Registry)"}],"container-title":["ImmunoHorizons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/5\/7\/581\/60186579\/ih2100063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/5\/7\/581\/60186579\/ih2100063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T02:44:39Z","timestamp":1736131479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article\/5\/7\/581\/7778376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.4049\/immunohorizons.2100063","relation":{},"ISSN":["2573-7732"],"issn-type":[{"value":"2573-7732","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2021,7,1]]}}}